Establishing the full repertoire of Gpr119-activated intestinal mechanisms that enhance not only GLP-1 but also PYY-mediated responses with consequent antihyperglycemic effects now provides an optimal platform for a high-affinity Gpr119 agonist to treat diabetes and obesity. The gene discussed is GLP1R; the disease is obesity disorder.